Table 7.

eGFR-adjusted dosages for DOACs and other dose reduction criteria.

eGFR category	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
$>$95 mL/min	150 mg twice a day	20 mg once daily	5 mg twice daily	60 mg once daily
50–94 mL/min	150 mg twice a day	20 mg once daily	5 mg twice daily	60 mg once daily
30–49 mL/min	110 mg twice a day	15 mg once daily	5 mg twice daily	30 mg once daily
15–29 mL/min	Do not use	15 mg once daily	2.5 mg twice daily	30 mg once daily
Dialysis	Do not use	Do not use	Do not use	Do not use
Other dose reduction criteria:	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
	Age $>$80 years old;	Not recommended if concomitant use of:	At least 2 of the following:	At least 2 of the following:
	Concomitant Verapamil treatment;	CYP3A4 inhibitors and/or inducers;	Age $>$80 years old;	CrCl 15–50 mL/min;
	Consider dose reduction according to RBR if: high bleeding risk pathology [e.g., GERD, esophagitis, gastritis, etc.]	P Glycoprotein inhibitors;	Body weight 60 kg;	Body Weight 60 kg;
		Systemic azole antifungal drugs	Serum Cr levels $>$1.5 mg/dL	Concomitant use of Dronedarone, Erythromicin, Ciclosporin or Ketoconazole

eGFR, estimated glomerular filtration rate; mL/min, milliliter/minute; RBR, risk-to-benefit-ratio; GERD, gastroesophageal reflux disease; CYP, cytochromes P450; CrCl, creatinine clearance; DOACs, direct oral anticoagulants.